Ozempic semaglutide injection for type 2 diabetes: what the evidence shows

What the regulatory record says about Ozempic's UK licence

The MHRA's position is unambiguous. Ozempic (semaglutide at doses of 0.5mg, 1mg and 2mg) is authorised in the UK as a treatment for adults with type 2 diabetes, to improve blood-glucose control alongside diet and exercise. That licence has never extended to weight management. This is worth stating plainly because Ozempic and Wegovy are both semaglutide, and the overlap causes genuine confusion. The active molecule is the same; the licences are entirely different. NHS guidance covers semaglutide in full on the NHS medicines pages, separating the diabetes and weight-loss indications clearly.

The MHRA has repeatedly highlighted concerns about semaglutide being obtained and used outside its licensed purpose. Shortages of Ozempic during 2023 and 2024 were in part attributed to off-label demand, which left people with type 2 diabetes struggling to access a medicine they needed for blood-sugar control. That context isn't incidental, it shapes how seriously regulators treat unlicensed dispensing of this class of medicine.

If you have type 2 diabetes and your GP or diabetes specialist has prescribed Ozempic, that is a straightforward licensed use. Questions about your dose, how you inject, what side effects to watch for, and whether Ozempic is still the right choice for you belong with the clinical team managing your diabetes. You can find detailed patient-level information in the Ozempic Summary of Product Characteristics on the eMC.

Semaglutide for weight loss: the evidence that led to a separate product

The reason Wegovy exists as a distinct product (rather than Ozempic simply being prescribed at a higher dose for weight) is that the clinical evidence was developed separately, at a higher dose (2.4mg weekly, now extended to 7.2mg), and submitted for a distinct marketing authorisation. The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with obesity or overweight and at least one weight-related condition but without diabetes. Over 68 weeks, participants receiving 2.4mg weekly semaglutide lost around 15% of body weight on average, roughly five times the placebo group's loss. That trial formed the basis of NICE's recommendation of semaglutide for weight management (TA875), which sits on a separate regulatory and clinical footing from Ozempic's diabetes authorisation.

Wegovy's injection pen looks similar to Ozempic's, but the dose ladder is different and the clinical oversight required is different. A page exploring whether semaglutide injection is the same as Ozempic sets this out in more detail. The short version: same molecule, entirely different licensed purpose, dose, and prescribing pathway. Conflating the two is one of the commonest errors we see from people researching this area.

It's also worth knowing that a third oral semaglutide product now exists for weight loss. The MHRA approved Wegovy tablets in June 2026, making them the first oral GLP-1 medicine licensed for weight management in the UK. These are not Rybelsus, Rybelsus tablets are semaglutide at lower doses licensed for type 2 diabetes, not weight loss. The dose schedule and indication are distinct.

Safety considerations specific to semaglutide-class injections

Whether someone is using semaglutide for diabetes or weight management, the safety profile shares common ground. Gastrointestinal effects (nausea, loose stools, reflux, reduced appetite) are the most frequently reported, particularly when starting or after a dose step-up. They tend to ease as the body adjusts, though that timeline varies considerably between individuals.

More serious effects require prompt attention. Severe, persistent abdominal pain that reaches into the back (with or without vomiting) should be assessed urgently because acute pancreatitis, though uncommon, is a recognised risk with this class. The MHRA issued a Drug Safety Update on this in January 2026. Anyone experiencing these symptoms should contact their GP or NHS 111 without delay; a full list of adverse effects worth knowing about is covered on our semaglutide injection side effects page.

Ozempic is not recommended during pregnancy, while breastfeeding, or when trying to conceive. Anyone in these situations should discuss treatment options with their GP or obstetric team. Under-18s are outside the licensed population for this medicine. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use GLP-1 receptor agonists; this is a contraindication covered in the SmPC and should be discussed with a specialist.

What IS licensed for weight loss in the UK, and how to access it through a regulated pharmacy

For adults who are looking to address weight rather than manage diabetes, two injectable medicines hold a current UK weight-management licence: Wegovy (semaglutide injection) and Mounjaro (tirzepatide). If you want to understand exactly how the semaglutide injection works as a licensed weight-loss treatment, our dedicated page covers the mechanism, dosing, and what to expect in detail. Mounjaro is a dual GIP and GLP-1 receptor agonist (the only one of its kind licensed here) and SURMOUNT-1 trial data showed average weight reductions of around 20% at the highest dose over 72 weeks. NICE recommended tirzepatide for eligible adults in December 2024 (TA1026). You can read more about how these two options compare on our Wegovy overview page or explore the broader weight-loss treatment options we offer.

At nume, our GPhC-registered pharmacy (premises registration 9012878, verifiable at the GPhC register) dispenses Wegovy and Mounjaro for weight management following same-day clinical review by a GPhC-registered Independent Prescriber. A real clinician reads your consultation answers (not software) and your prescriber assesses full medical history, current medicines, and eligibility before anything is approved. If you've seen references to the skinny pen semaglutide online and wondered what that actually means in a regulated context, our page explains the terminology and how it relates to licensed products. If suitable, your order is dispatched the same day you order before 12pm, arriving via DPD the next working day in plain, unbranded packaging with a tracking notification to your phone. Anyone curious about what the consultation process looks like can find the detail on our about us page.

If you're considering weight-loss treatment and want to understand your options properly, starting a free consultation with our prescribers is the place to begin. We don't prescribe Ozempic for weight loss (because it isn't licensed for that purpose) but we can assess whether Wegovy or Mounjaro is clinically appropriate for you, and our Ozempic semaglutide pen page explains clearly why the pen you may have read about differs from the weight-management products we do prescribe.